rated dose of Photofrin (Axcan Pharma, Birmingham, AL)-mediated photodynamic therapy and showed encouraging efficacy. The primary objectives of this phase II study were to determine the efficacy and toxicities of i.p. photodynamic therapy in patients with peritoneal carcinomatosis and sarcomatosis. Experimental Design: Patients received Photofrin 2.5 mg/kg i.v. 48 hours before debulking surgery. Intraoperative laser light was delivered to the peritoneal surfaces of the abdomen and pelvis. The outcomes of interest were (a) complete response, (b) failure-free survival time, and (c) overall survival time. Photosensitizer levels in tumor and normal tissues were measured. Results: One hundred patients were enrolled into one of three strata (33 ovarian, 37 gastrointestinal, and 30 sarcoma). Twenty-nine patients did not receive light treatment. All 100 patients had progressed by the time of statistical analysis. The median failure-free survival and overall survival by strata were ovarian, 2.1and 20.1months; gastrointestinal cancers,1.8 and11.1months; sarcoma, 3.7 and 21.9 months. Substantial fluid shifts were observed postoperatively, and the major toxicities were related to volume overload. Two patients died in the immediate postoperative period from bleeding, sepsis, adult respiratory distress syndrome, and cardiac ischemia. Conclusions: Intraperitoneal Photofrin-mediated photodynamic therapy is feasible but does not lead to significant objective complete responses or long-term tumor control. Heterogeneity in photosensitizer uptake and tumor oxygenation, lack of tumor specificity for photosensitizeruptake, and the heterogeneity in tissue optical properties may account for the lack of efficacy observed. Photody amic therapy is a treatme t modality usi g a photose sitizi g age t a d light to kill cells i the prese ce of oxyge . Cli ical use of photody amic therapy requires a photose sitizi g age t, oxyge , a d light of a wavele gth specific to the absorptio characteristics of the photose sitizer. O e appeal of photody amic therapy i o cology has bee the lo ger retetio of some photose sitizers i malig a t, relative to ormal tissues (1-3). The pote tial for effective treatme t of ca cer with mi imal ormal tissue toxicity has prompted a i terest i studyi g photody amic therapy as a ca cer treatme t.
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Timothy Zhu, 1 Carmen Rodriguez, 1 Andreea Dimofte, 1 Francis Spitz, 2 ary Putt, 3 Stephen C. Rubin, 5 Chandrakala enon, 2 Hsing-Wen Wang, 1, 4 Daniel Shin, 1 ArjunYodh, 1, 4 and Eli Glatstein 1 Abstract Purpose: A previous phase I trial of i.p. photodynamic therapy established the maximally tolePhotody amic therapy is a treatme t modality usi g a photose sitizi g age t a d light to kill cells i the prese ce of oxyge . Cli ical use of photody amic therapy requires a photose sitizi g age t, oxyge , a d light of a wavele gth specific to the absorptio characteristics of the photose sitizer. O e appeal of photody amic therapy i o cology has bee the lo ger retetio of some photose sitizers i malig a t, relative to ormal tissues (1) (2) (3) . The pote tial for effective treatme t of ca cer with mi imal ormal tissue toxicity has prompted a i terest i studyi g photody amic therapy as a ca cer treatme t.
Despite a large body of data explori g the basic biology of photody amic therapy i a imal models, photody amic therapy has bee used i freque tly i the i traoperative setti g. Early phase cli ical studies are importa t both to determi e whether the therapy shows sufficie t efficacy to proceed to ra domized trials, as well as to determi e whether the results from a imal models have releva ce i a cli ical setti g. A phase I study of surgery i combi atio with photody amic therapy with laser light a d Photofri (Axca Pharma, Birmi gham, AL) was co ducted by the Surgery a d Radiatio O cology Bra ches of the Natio al Ca cer I stitute for dissemi ated i.p. malig a cies (4, 5) . Fifty-four patie ts with perito eal carciomatosis who u derwe t debulki g surgery were treated o the study. The photody amic therapy dose was seque tially escalated by i creasi g the se sitizer dose from 1.5 to 2.5 mg/kg, by shorte i g the i terval betwee se sitizer i jectio a d the surgery, a d by i creasi g the light dose. With the use of 630 m red light, photody amic therapy i duced small bowel edema a d resulted i three small bowel perforatio s. Because of this tra smural pe etratio by red light, less pe etrati g 514-m gree light was used for the large field exposures to the bowel a d mese tery thereafter. This allowed further light dose escalatio , a d o additio al small bowel complicatio s were see . Dose-limiti g toxicity was e cou tered i two of three patie ts at the highest dose (5.0 J/cm 2 ) of gree light with boost. These two patie ts both developed pleural effusio s that required thorace tesis a d postoperative respiratory support for 7 to 9 days. The maximally tolerated dose of photody amic therapy 48 hours after i.v. admi istratio of of the U iversity of Pe sylva ia a d the U iversity of Pe sylva ia Photofri (2.5 mg/kg) was determi ed to be 3.75 J/cm 2 doses have bee made si ce the i itial report was published.
Hollywood, CA) to reduce u wa ted activatio of the photose sitizer.
The follow-up of these patie ts has bee updated (5 used to 10 of i cide t i te sity. a d malig a t tissues a d to assess the optical properties of perito eal
The light doses were determi ed previously i a phase I trial (4, 5). tissues. Efficacy variables i cluded complete respo se rate as well as
The mese tery, the large bowel, a d the small bowel were treated with failure-free a d overall survival. A total of 100 patie ts were e rolled i 532-m gree light at a dose of 2.5 J/cm 2 usi g a flat-cut optical fiber.
this phase II study. All patie ts were treated with the same photody amic The bowel was positio ed u der a circular beam of light a d was therapy regime as defi ed i the previously reported phase I study treated i segme ts seque tially. After delivery of gree light to the (4, 5) . Photofri (porfimer sodium) 2.5 mg/kg was admi istered i.v.
bowel a d before 630-m light delivery to the rest of the perito eal f48 hours before the pla ed laparotomy. Surgical resectio a d light surfaces with 630-m red light, the abdome was filled with a dilute delivery were do e as described below. The protocol permitted light solutio of i tralipid (0.01%) i sterile ormal sali e. This was used to admi istratio to a y patie t whose perito eal disease was resected to a e ha ce scatteri g of the light. The 630-m light to the perito eal thick ess of V5 mm. Toxicity was scored usi g the Natio al Ca cer cavity was delivered with a optical fiber sheathed withi a modified I stitute Cooperative Group Commo Toxicity Criteria, versio 1. . Patie ts received o e course of light therapy matosis who had exhausted curative therapies, age > 18 years, sig ed at the time of surgery. Followi g the completio of light admi istrai formed co se t, a d abse ce of dista t metastatic disease. Patie ts tio , the sterile photodiodes were removed from the abdome . I the were e tered i to o e of three strata: ovaria ca cer, sarcoma, a d immediate postoperative period a d after discharge, patie ts were gastroi testi al ca cers.
i structed to avoid direct su light for 30 to 60 days after Photofri Patie ts were excluded based o the followi g criteria: borderli e admi istratio . tumors of low malig a t pote tial; ulcerative colitis; regio al e teritis;
Patie ts were tra sferred to the i te sive care u it immediately after i ability to tolerate ge eral a esthesia; HIV positivity; white cou t surgery a d were, i ge eral, i tubated for at least 24 hours after the 3 3 <2,000 per mm or platelet cou t <100,000 per mm ; serum creati i e procedure. Sig ifica t fluid shifts were observed postoperatively, which z2.5 mg/dL; severe liver disease, i cludi g cirrhosis, grade 3 to 4 ecessitated massive fluid resuscitatio as previously described (7). elevatio s i liver fu ctio studies, or bilirubi i excess of 1.5 mg/dL, Pati nt follow-up. Patie ts were see 1 mo th after their discharge a d preg a t or lactati g patie ts. Patie ts who i the opi io of either i the outpatie t cli ics at the Hospital of the U iversity of the atte di g surgeo could ot be debulked to a thick ess of V5 mm Pe sylva ia or by the primary referri g physicia to assess treatme to preoperative evaluatio were also excluded. related toxicities. The patie ts were the see 3 mo ths after the Patie ts u derwe t a preoperative evaluatio that i cluded a history procedure a d every 3 mo ths for the first 24 mo ths. A computerized a d physical exami atio , imagi g studies of the abdome a d pelvis tomography sca of the abdome a d pelvis was do e every 3 mo ths (computerized tomography a d/or mag etic imagi g reso a ce), a duri g the first year after treatme t, every 6 mo ths the seco d year, chest radiograph a d laboratory studies i cludi g a HIV a tibody test. a d the as cli ically i dicated thereafter. Other tests were do e as Other tests, i cludi g tests to exclude dista t metastases, were do e as cli ically i dicated. At the 6-mo th follow-up visit, if the patie t had cli ically i dicated.
o cli ical evide ce of disease, a mi ilaparotomy or a laparoscopy was The protocol was co ducted u der a i vestigator-spo sored do e for pathologic restagi g. Biopsies, if cli ically i dicated, were I vestigatio al New Drug Applicatio with the U.S. Food a d Drug take from all regio s that could be safely exposed at the time of Admi istratio . This study was do e i accorda ce with the Declaralaparoscopy/mi ilaparotomy. A laparoscopy was do e i five patie ts, tio of Helsi ki a d had approval from the I stitutio al Review Board a d a mi ilaparotomy was do e i seve patie ts. Photos nsitiz r conc ntration in tissu sampl s. Portio s of tumor a d resected ormal tissues were placed i specime co tai ers, protected from visible light, a d froze at 70jC. The assay for porfimer sodium qua titatio was based o a previous report (8) . Tissue samples were thawed to room temperature a d weighed a d, depe di g o the amou t available, f10 to f50 mg of tissue was placed i a vial with 0.150 to 0.500 mL, respectively, of the tissue solubilizer Solvable (Packard, Meride , CT). The vial was capped a d heated at 50jC over ight (20 F 2 hours) i the dark. The solutio was cooled to room temperature, a equal volume of distilled water was added a d, after thorough mixi g, it was tra sferred to a quartz cuvette of 0.2 mL (10-mg samples) or 0.6 mL (50-mg samples) capacity. The fluoresce ce of the solubilized sample was measured by a spectrofluorometer (FluoroMax-3, Jobi Yvo , I c., Ediso , NJ) with k ex of 405 m a d k em of 627 m. Porfimer sodium co ce tratio i the tissue was calculated based o the i crease i fluoresce ce resulti g from the additio of a k ow amou t of porfimer sodium to each sample after its i itial readi g. Triplicates of each sample were ru .
Photofri co ce tratio s were determi ed i the tumors of 48 patie ts with 26 patie ts havi g multiple tumor tissues sampled from various sites. Withi each stratum, we described these co ce tratio s by pooli g all of the measureme ts a d determi i g the media a d ra ge (mi imum a d maximum co ce tratio ). For each patie t with multiple measureme ts, we determi ed a overall mea Photofri co ce tratio , a SD, a d a coefficie t of variatio perce t for each patie t [CV% = (SD / mea ) 100]. We summarized the coefficie t of variatio s withi each strata usi g the media a d the ra ge. Stratumspecific mea s of tumor Photofri co ce tratio were calculated usi g i dividual measureme ts for patie ts with exactly o e measureme t a d from withi -patie t mea s for patie ts with multiple samples. For co siste cy with a alyses to be reported later, the mea for each patie t was calculated by first averagi g across each site with multiple measureme ts a d the formi g a overall mea . Statistical a alyses were do e usi g the software package SPSS (SPSS, I c., Chicago, IL) or R 2.0 (http://www.r-project.org).
Summary statistics for tumor to ormal ratios of Photofri i large bowel without mucosa a d small bowel without mucosa were determi ed usi g o ly those patie ts with samples from tumor as well as ormal bowel tissues. We first averaged Photofri co ce tratio s across all tumor samples a d across all samples of either small or large bowel withi a patie t. We the formed a ratio for each patie t a d summarized the results usi g media s a d ra ges.
Statistical consid rations. This study was desig ed to evaluate toxicity a d efficacy of photody amic therapy for i.p. malig a cies. Patie ts were e rolled i to o e of three disease strata: ovaria ca cer, gastroi testi al ca cers, a d sarcoma. Toxicities were graded usi g Commo Toxicity Criteria, versio 1.0. Respo se was coded as either complete respo se ( o evide ce of abdomi al disease) or treatme t failure ( ew or recurre t abdomi al disease) based o laparoscopy a d/or radiographic fi di gs at 6 mo ths after surgery. The seco dary objectives were to estimate failure-free a d overall survival withi each disease stratum a d to characterize tissue Photofri co cetratio s. Failure-free survival was measured from study e try (date of Photofri i jectio ) to first docume ted progressio , death due to a y cause, or last patie t co tact. For patie ts who were fou d i eligible to receive photody amic therapy at the time of surgery, failure-free survival was measured from date of Photofri i jectio to date of surgery, which was 2 days. Overall survival was measured from study e try to death due to a y cause or last patie t co tact i all patie ts. Failure-time a alyses were based o follow-up data available as of Ja uary 2005. The primary a alyses of patie t characteristics, toxicity, complete respo se rate failure-free survival, a d overall survival were based o the i te t-to-treat populatio (i.e., all patie ts who received Photofri i jectio , regardless of whether photody amic light therapy was admi istered). Patie ts who did ot receive photody amic light therapy were excluded from the decisio to termi ate the study early i the two-stage desig but were i cluded i the primary a alyses. A subset a alysis was also do e based o patie ts who received both drug a d light. Media failure-free a d overall survival were estimated usi g the Kapla a d Meier method with 95% co fide ce i tervals for media s based o Gree wood's formula (9, 10). Statistical a alyses were do e usi g the software package SPSS (SPSS) or R 2.0 (http://www.r-project.org).
Pati nt charact ristics. As show i Fig. 1 , 100 patie ts were e rolled i to three strata (33 ovaria ca cer, 37 gastroi testi al ca cer, a d 30 sarcoma patie ts) a d received Photofri i jectio 24 hours before surgery: all 100 patie ts comprise the i te t-to-treat populatio . Twe ty-i e patie ts were ot eligible for i traoperative light delivery due to tumor ot resectable to <5 mm (26 patie ts), localized disease o ly (two patie ts), or malig a cy could ot be co firmed by pathology (o e patie t). Seve ty-o e patie ts received i traoperative light therapy (23 ovaria , 22 gastroi testi al, a d 26 sarcoma ca cer patie ts). Patie ts with gastroi testi al ca cers a d ovaria ca cer were more likely to have disease that could ot be resected to the thick ess required for light therapy.
As prese ted i Table 1 , approximately half of the gastroi testi al ca cer a d sarcoma patie ts were male. The average age at e rollme t was f50 years. The vast majority of patie ts were Easter Cooperative O cology Group performa ce status 0 or 1. All ovaria ca cer patie ts had u dergo e surgery a d chemotherapy before photody amic therapy. All sarcoma patie ts had u dergo e surgery, a d some had received chemotherapy (10 of 30) a d radiotherapy (4 of 30). The majority of gastroi testi al ca cer patie ts (32 of 37) had u dergo e surgery, a d most had also received chemotherapy (29 of 37). O ly two gastroi testi al patie ts had previously u dergo e radiotherapy, whereas four patie ts had received o preoperative therapies. Tr atm nt outcom . The media pote tial follow-up for all 100 patie ts was 51 mo ths. For the 19 patie ts alive, the media pote tial follow-up was 46 mo ths. As prese ted i Table 2 , all 100 patie ts had progressed by the time of statistical a alysis. Treatme t respo se was assessed o a co ti uous basis. At least o e respo se was observed i the first 14 patie ts e rolled i each cohort. At 6 mo ths after photody amic therapy, a total of 3 of 33 (9.1%) ovaria , 2 of 37 (5.4%) gastroi testi al, a d 4 of 30 (13.3%) sarcoma ca cer patie ts had achieved a complete respo se, as assessed by mi ilaparotomy or laparoscopy. Figure 2A to C displays treatme t outcome for the i te t-totreat populatio . The media failure-free survival a d overall survival by strata were ovaria , 2.1 mo ths [95% co fide ce i terval (95% CI), 0.5-3.7 mo ths] a d 20.1 mo ths (95% CI, 13.9-26.4 mo ths); gastroi testi al ca cers, 1.8 mo ths (95% CI, 0.0-4.0 mo ths) a d 11.1 mo ths (95% CI, 4.9-17.2 mo ths); sarcoma, 3.7 mo ths (95% CI, 3.1-4.4 mo ths) a d 21.9 mo ths (95% CI, 10.9-33.0 mo ths). Figure 2D to F shows treatme t outcome for the photody amic therapytreated subset of patie ts. The media failure-free survival a d overall survival by strata were ovaria , 3.0 mo ths (95% CI, 2.5-3.5 mo ths) a d 22.0 mo ths (95% CI, 14.1-30.0 mo ths); gastroi testi al ca cers, 3.3 mo ths (95% CI, 2.1-4.6 mo ths) a d 13.2 mo ths (95% CI, 4.9-21.5 mo ths); sarcoma, 4.0 mo ths (95% CI, 1.9-6.1 mo ths) a d 21.9 mo ths (95% CI, 3.6-40.3 mo ths).
Toxicity. Toxicities related to photody amic therapy i all patie ts treated are show i Table 3 . The most commo toxicity observed postoperatively was a capillary leak sy drome. Photos nsitiz r conc ntration in tumor sampl s. Uptake of the photose sitizer Photofri was measured i a total of 143 tumor samples from 48 patie ts (Fig. 3) . I ge eral, a high degree of i trapatie t a d i terpatie t heteroge eity i Photofri levels was observed. Forty-eight patie ts co tributed multiple tumor samples. I 30 tumor samples from 10 ovaria ca cer patie ts, the media tumor Photofri co ce tratio was 3.37 g/mL (ra ge, 1.40-6.33 g/mL; Fig. 3A) . Substa tial i trapatie t variability was oted especially i patie t 7 (six samples, CV% = 56%) a d patie t 10 (five samples, CV% = 45%). The Photofri co ce tratio s were lower i 31 tumor samples from 15 sarcoma patie ts compared with the ovaria ca cer cohort (media , 2.10 g/mL; ra ge, 0.49-7.83 g/mL; Fig. 3B ). Samples from patie t 12 also displayed high i trapatie t variability (five samples, CV% = 44%). I 82 tumor samples from 23 gastroi testi al ca cer patie ts, the media tumor Photofri co ce tratio was 2.88 g/mL (ra ge, 0.13-6.23 g/mL; Fig. 3C ). Modest i trapatie t variability was observed for most patie ts, with the exceptio of patie t 21, who exhibited a si gle high co ce tratio i a total of seve samples (CV% = 117%).
Also of ote is patie t 18, the si gle patie t with small bowel disease, whose tumor samples displayed high tumor Photofri co ce tratio s (media , 5.21 g/mL) yet low i trapatie t variability (five samples from perito eum, CV% = 13%). I teresti gly, patie t 22 with gastric ca cer, exhibited low variability (CV% = 22%) despite that fact that 10 tumor samples were draw from stomach, upper quadra t of perito eum, a d other locatio s. I ge eral, tumors of patie ts with pseudomyxoma perito eii (patie ts 11, 20, a d 23) displayed lower tumor Photofri co ce tratio s, with the exceptio of o e sample from patie t 23, which had a co ce tratio of 3.64 g/mL. Tumor-to-ormal (T/N) tissue ratios of Photofri uptake were calculated for the large bowel a d small bowel with a d without mucosa (i.e., a toxicitylimiti g ormal tissue). Without mucosa, the media T/N for small bowel (four patie ts) was 2.1 (ra ge, 1.3-3.6), a d the media T/N for large bowel (three patie ts) was 2.1 (ra ge, 0.8-4.5). The media T/N ratio was 1.1 for large bowel samples with mucosa a d 2.1 for samples without mucosa.
Discussion
Treatme ts for patie ts with perito eal carci omatosis are limited a d i clude systemic chemotherapy, whole abdomi al radiotherapy, a d debulki g surgery i combi atio with hyperthermic perito eal perfusio with chemotherapy. No curative treatme t exists, i ge eral, for this group of patie ts.
Photody amic therapy is a ca cer treatme t that employs the use of a photose sitizi g age t a d laser light of a specific wavele gth to activate the photose sitizer i the prese ce of oxyge . The effective depth of cellular damage of photodyamic therapy i tissue is depe de t upo several factors, i cludi g photose sitizer co ce tratio , wavele gth of laser light, amou t of tissue oxyge , a d the optical properties of the u derlyi g tissues. I ge eral, photody amic therapy is a superficial treatme t with a effective depth of cellular damage for Photofri -mediated photody amic therapy of 2 to 5 mm (1, 2). The superficial ature of Photofri -mediated photodyamic therapy makes this treatme t a pote tially ideal therapy for surface malig a cies, such as ca cers, which have spread to the serosal surfaces of the perito eum a d pleura. The limited pe etratio of photody amic therapy tissue effect would theoretically limit the pote tial for damagi g u derlyi g critical orga s. We have rece tly reported our experie ce with treati g o -small cell lu g ca cer, which has spread to the pleural surface (11). That study showed that excelle t local co trol could be achieved with acceptable toxicity usi g Photofri -mediated photody amic therapy. Furthermore, we showed that the media survival of these patie ts exceeded what would ormally be expected i patie ts with pleural carci omatosis. This study provides some evide ce that photody amic therapy might be effective as a treatme t for patie ts with malig a cies that have spread to serosal surfaces.
Patie ts with malig a cies that spread to the perito eum (i cludi g patie ts with ovaria ca cer, sarcoma, a d gastroi testi al ca cers) have few to o curative treatme t optio s. These patie ts prese t with abdomi al pai , altered bowel fu ctio , ascites, a d recurre t small bowel obstructio . Chemotherapy is ofte admi istered to these patie ts, especially those with ovaria ca cer a d gastroi testi al malig acies. The subset of sarcoma patie ts with gastroi testi al stromal tumors is usually treated with imati ib mesylate (12, 13) . Whole abdomi al radiotherapy is ot a curative treatme t optio for patie ts with perito eal carci omatosis a d sarcomatosis because the u derlyi g abdomi al orga s limit the ability to deliver a curative dose of radiatio . Radical surgical approaches have bee attempted i these patie ts but are u likely to sterilize the perito eum.
The phase I trial of Photofri -mediated photody amic therapy completed at the Natio al Ca cer I stitute (4, 5) showed that this procedure could be do e with acceptable toxicities. E couragi g prelimi ary respo ses, especially i ovaria ca cer patie ts, provided the ratio ale for performi g this phase II study. Our results show that Photofri -mediated photody amic therapy is feasible after surgical debulki g but does ot lead to co trol of perito eal carci omatosis or sarcomatosis after surgical debulki g. Some of our patie ts had cli ical be efit from i.p. photody amic therapy that did ot qualify as a complete respo se. Reductio i the umber of perito eal odules a d the elimi atio of the eed for abdomi al parace tesis were observed i selected i dividuals but could ot be scored as a complete respo se. It should be kept i mi d that the criteria used for efficacy i this study were rigorous a d required the complete abse ce of cli ical, radiographic, a d, i some cases, pathologic disease withi the abdome . This is a sta dard of efficacy that is higher tha is typically used i studies of chemotherapy i this patie t populatio . Notwithsta di g the strict criteria used, complete O e of the reported theoretical adva tages of photody amic respo ses to Photofri -mediated photody amic therapy were u commo , a d failure-free survival was short i all disease cohorts. The toxicity caused by surgical debulki g a d Photofri -mediated photody amic therapy was substa tial, i cludi g a capillary leak sy drome (7, 14) observed i ma y patie ts i the immediate postoperative period. It is likely that this systemic toxicity of i.p. photody amic therapy is a result of tissue damage to the serosal surfaces of the perito eum similar to that observed i bur victims. The prese ce of this toxicity a d the abse ce of a sig ifica t therapeutic respo se suggest that i.p. photody amic therapy has a arrow therapeutic ratio. therapy as a ca cer treatme t is that systemically admi istered www.aacrjournals.org photose sitizers i a imal models have greater rete tio i ca cers compared with selected ormal tissues (2, 3, 15) . These studies, however, compared the uptake of photose sitizers i tumor to that i ormal tissues, such as muscle or ski , which are ot particularly releva t to ormal tissues at risk for toxicity from i.p. photody amic therapy. If co firmed i huma cli ical trials, the selectivity of photose sitizers i tumor compared with releva t ormal tissues would provide a e ha ced therapeutic ratio for photody amic therapy. The eed for tumor selectivity of photose sitizer rete tio is particularly importa t whe co sideri g treatme t of large surface areas, such as the perito eum, where a large umber of se sitive ormal tissues are at risk for toxicity a d where activatio of a photose sitizer i large surface areas has bee associated with systemic i flammatory respo se sy drome or capillary leak sy drome (16). The photose sitizer uptake measureme ts i patie ts o this trial show that absolute tissue levels i huma tumors are similar to those described for tumors i muri e models (17, 18). However, tumor-to-ormal tissue (T/N) ratios for releva t ormal tissues, such as the large bowel, were very modest, with media values ra gi g betwee 1.1 a d 2.1, depe di g o whether tissue co tai ed mucosa (data ot show ). Furthermore, substa tial heteroge eity was fou d amo g patie ts, as could be expected from the variability amo g absolute tumor levels of drug withi disease strata. Such heteroge eity would be expected to limit the photody amic therapy dose that could be achieved before reachi g cli ical toxicity a d likely co tributes to the disappoi ti g cli ical fi di gs described above. I a separate cli ical trial, Photofri measureme ts i several patie ts with o -small cell lu g ca cer with pleural spread (11) also ide tified modest drug selectivity betwee tumor a d releva t ormal tissues ( ormal pleura a d lu g). T/N ratios withi specific tissue types were co siste t amo g the first three patie ts evaluated o this study, but it is too early to assess the degree of i trapatie t a d i terpatie t heteroge eity i tissue Photofri uptake o this trial i o -small cell lu g ca cer. A more expa sive report with detailed statistical a alysis of tumor a d ormal tissue levels of Photofri uptake i the patie ts of the i.p. photody amic therapy trial is curre tly bei g prepared. Overall, these data highlight the importa ce of assessi g tumor to ormal tissue ratios i huma tumors a d releva t ormal tissues as part of the cli ical evaluatio of photody amic therapy.
The photose sitizer measureme ts described i this study a d i our previous reports the delivery of drugs to tumor odules o the perito eal surface measureme t of both scattered a d i cide t light will be a d are pote tially releva t to the delivery of chemotherapy ecessary to adequately co trol light dose depositio i tissues. drugs to perito eal tumors. We have previously show that I summary, we have show that i.p. Photofri -mediated Photofri is prese t i tumor odules as small as 1 mm i size photody amic therapy is feasible but does ot lead to (17, 19). I additio , a prelimi ary evaluatio of photose sisig ifica t objective respo ses or tumor co trol. Heteroge eity tizer uptake a d oxyge levels i these patie ts also suggested i photose sitizer uptake a d tumor oxyge atio , lack of substa tial i terpatie t a d i trapatie t heteroge eity i sig ifica t tumor specificity for photose sitizer uptake, a d the Photofri a d oxyge levels i tumor (19). The photody amic heteroge eity i tissue optical properties may accou t for the process is depe de t upo the prese ce of adequate photoselack of efficacy observed. Photofri -mediated i.p. photodysitizer a d oxyge (2) . Either of these factors may limit the amic therapy delivered as a si gle treatme t is u likely to efficacy of the treatme t. A additio al factor of importa ce is lead to a sustai ed complete respo se i patie ts with i.p. that a major mecha ism of actio for Photofri -mediated malig a cies who have gross disease. This situatio is similar photody amic therapy is a vascular effect, which may ot be to the early developme t of radiatio therapy where it was optimal i a cli ical setti g where small volume disease is discovered that si gle, large doses of io izi g radiatio were treated after debulki g surgery.
ot as effective as fractio ated treatme t. The use of methods to The perito eum is a complex cavity with a surface area e ha ce the efficacy of photody amic therapy agai st tumor similar to the exter al body surface area (4) . There are regio s compared with ormal tissues, improved tech iques for light of the perito eal cavity that are difficult to access for light delivery, a d fractio ated photody amic therapy are reasodelivery, such as the diaphragmatic surfaces a d deep withi able approaches to co sider i future studies of i.p. photodythe pelvis. We have also previously show that there is amic therapy. heteroge eity i the optical properties i perito eal light delivery a d light dose absorbed i various regio s withi a
